China Anti-tumor Drugs Market Report, 2007
  • Jun/2007
  • Hard Copy
  • USD $299
  • Pages:16
  • Single User License
    (PDF Unprintable)       
  • USD $299
  • Code:
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $598
  • Hard Copy + Single User License
  • USD $499
      

The anti-tumor drugs market operated well in 2006, and the total sales volume amounted to USD 34.6 billion, up 20.5% from a year earlier, and the growth margin ranked the first place among all the treatment categories to be the most important drive force for promoting the global drugs market. According to the increase trend in recent five years, it is forecasted that the anti-tumor drugs will probably be the unit product with the largest sales income in the global drugs market.

According to the forecast of IXIS, the molecule-targeted drugs will stand out singly, its annual compound growth rate (ACGR) will reach 23% in 2005-2010, and the market share will be from 39% in 2005 to 53.6% in 2010.

The total sales of anti-tumor drugs (except traditional Chinese medicine) in China amounted to RMB 6.002 billion in 2006, up 23.94% year-on-year. It is forecasted that the total sales of anti-tumor drugs (except traditional Chinese medicine) in China will reach RMB 7.6 billion in 2007, rising above 25% from a year earlier.

Sales Change Trend of China Anti-tumor Drugs (except Traditional Chinese Medicine)


Market Shares Change of China Anti-tumor Drugs (except Traditional Chinese Medicine)




1 Status Quo and Development Trend of Global Anti-tumor Drugs Market
1.1 Classified Anti-tumor drugs become the rapidest increase field in global drugs market
1.2 Molecule-targeted drugs of anti-tumor increases fast
1.3 R&D of anti-tumor drugs field is still active

2 Chinese Anti-tumor Drugs Market
2.1 Chinese anti-tumor drugs Market
2.2 Chinese enterprises

3 Major Companies
3.1 Hengrui
3.2 Hansoh
3.3 Hisun
3.4 Wanle
Global Drugs Industry Development Trend
R/E Ratio Change of Roche, 2001-2007
Tumor Patient Occurrence Rate in China
Sales Change of Anti-tumor drugs (except Traditional Chinese Medicine) in China
Forecast of Hengrui Sales Income
Main Anti-tumor Drugs Increase of Hengrui
Docetaxel Sales Income and Increase of Hengrui
Oxaliplatin Sales Income and Increase of Hengrui
Irinotecan Hydrochloride Infusion Sales Income and Increase of Hengrui
Sales Income of Hansoh
Main Anti-tumor Drugs of Hansoh
Sales Income of Hisun
Main Anti-tumor Drugs of Hisun
Sales Income of Wanle
Current Equity Structure of Wanle
Top Ten Classified Drugs in Global Drugs Market by Sales, 2006
Forecast of Top Three Anti-tumor Drugs Increase
Forecast of Anti-tumor Drugs Market Shares of Key Companies
Top Global 500 Anti-tumor Drugs by Sales, 2005
Main Classifications of Anti-tumor Drugs in China
Chinese Enterprises with Sales Income of Anti-tumor Drugs above RMB 100 Million
Foreign Enterprises with Sales Income of Anti-tumor Drugs above RMB 100 Million
Market Shares Change Trend of China Anti-tumor Drugs (excluding Traditional Chinese Medicine)

China Blood Product Industry Report, 2020-2027

With the adjustment in the catalog of medicines covered by national medical insurance system, the scope and reimbursement ratio of almost all blood products for clinical use grow tremendously, which h...

China Medical Robot Industry Report, 2020-2026

Medical robot is the most promising segment of service robot market. By one estimate, globally 7,200 units of medical robots were sold and valued at $2.58 billion in 2019, compared with 5,100 units (u...

China In Vitro Diagnostic (IVD) Industry Report, 2019-2025

In vitro diagnosis (IVD) as a good way to make a rapid and definite diagnosis of diseases early, plays an increasingly crucial role in clinical medicine and related medical research fields. China’s IV...

China Aged Care Industry Report, 2019-2025

China’s society has aged before it gets rich. By the end of 2018, people aged over 60 had numbered 249.5 million in the country, or 17.9% of the total population, of which those aged over 65 were 167 ...

China Dental Industry Report, 2019-2025

Nowadays, the Chinese people have a growing awareness of oral health and healthy behaviors. 60.1% of residents have knowledge about oral health; 24.1% of 5-year-old children and 31.9% of 12-year-old c...

China Hospital Industry Report,2019-2025

The people’s growing awareness of health care and the acceleration of population aging have brought prosperity to China’s hospital industry. As of February 2019, there had been a total of 33,000 hospi...

China Dental Industry Report, 2017-2021

As living standards continue to improve and the awareness of oral health grows, consumers’ demand for dental services has kept increasing and the dental industry in China has witnessed robust developm...

China Interferon Industry Report, 2016-2021

Interferon is mainly used for the treatment of hepatitis B, hepatitis C, multiple sclerosis, condyloma acuminatum and other diseases. Wherein, IFN-α is mainly suitable for curing hepatitis B and hepat...

China Hospital Industry Report,2016-2020

In recent years, "Opinions on Promoting the Development of Health Service Industry" and other related policies, the people’s growing awareness of health care and the acceleration of population aging h...

China Aged Care Industry Report, 2016-2020

China entered the aging society early in 1999. By the end of 2015, China’s population aged over 60 reached 222 million and the old-age dependency ratio 13.9%. By 2020, China’s population aged over 60 ...

China Medical Robotics Industry Report, 2016-2020

Medical robotics can be used in surgery, rescue, transport, care, rehabilitation, dispensing and so on for the sick and wounded. Especially, surgical, rehabilitation and dispensing robots are the R &a...

China Dental Industry Report, 2016-2020

The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental apparatus (equipments and consumables), dental medical services, etc. With ...

China Medical Imaging Diagnosis Industry Report, 2015-2019

Against the background of a surge in social demand, handsome profit and the favorable opportunity brought by health care reform, the medical imaging industry, especially medical imaging equipment indu...

China Heparin Industry Report, 2015-2018

As the world's largest heparin API producer and exporter, China seizes about 80% share of the global heparin API market. After the explosive growth in 2008-2010, the stagnant international market and ...

Global and China Stem Cell Industry Report, 2015-2018

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Currently, stem cells are used to treat hund...

China Hospital Industry Report, 2015-2018

Stimulated by the demand, the number of hospitals in China rose from 21,979 in 2011 to 26,479 at the end of May 2015, an increase of 4,500 in total. Among them, public hospitals showed an overall decl...

China Independent Clinical Laboratory Industry Report, 2015-2018

The independent clinical laboratory originated from the U.S. and is relatively mature in developed countries/regions like North America, Europe, and Japan, whose independent clinical laboratory market...

China Medical Robot Industry Report, 2014-2018

Medical robots can be applied to surgeries, rescue, transport, nursing and rehabilitation of the sick and wounded. Wherein, surgery and rehabilitation robots are two striking market segments. Due to ...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号